Releases

Media coverage

Newsletter

Subscribe to our newsletter

Archive


Apr 30, 2014

Norsk tekst lenger ned

Lytix Biopharma is attending Association for Cancer Immunotherapy (CIMT) meeting in Mainz, May  6-8 2014. The company’s scientific collaborator, Professor Gunnar Kvalheim (The Norwegian Radium Hospital), will present a poster and exciting results from preclinical studies with LTX-315 in the short talk session “New Targets & New Leads” on May 7, room Gutenberg A at 10:45AM.

The title of the talk is: “LTX-315 treatment induces complete and specific regression of disseminated tumors in a novel mesenchymal three tumor rat model.”

See the poster here.

See a twitter link here.

Lytix Biopharma is represented by Ali Areffard, Scientific Advisor Immuno-Oncology.

 

Norsk tekst

Lytix Biopharma skal delta på kreftimmunterapimøtet CIMT i Mainz 6.-8. mai 2014. Selskapets vitenskapelige samarbeidspartner, professor Gunnar Kvalheim (Radiumhospitalet), skal presentere en poster og spennende prekliniske resultater med LTX-315 under foredragstema “New Targets & New Leads” den 7. mai, rom Gutenberg A kl. 10:45.

Tittelen på foredraget er: “LTX-315 treatment induces complete and specific regression of disseminated tumors in a novel mesenchymal three tumor rat model.”

Se posteren her.

Se en twitter-link her.

Lytix Biopharma representeres ved Ali Areffard, vitenskapelig rådgiver immunonkologi.